AEMD Company Profile and Key Details

AEMD has shown mixed momentum, gaining 13.45% over the past week and -50.29% over the past quarter, though year-to-date performance is down -2.53%. Short-term trend indicators are bullishly aligned (SMA20 -7.25%, SMA50 -20.39%, SMA200 -79.69%). The stock’s 14-day RSI is 36.43 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.83% below its high and over 7.67% above its low. Average 10-day trading volume of 16.15 thousand shares is below the 3-month average of 43.91 thousand, indicating normal recent market interest.

Aethlon Medical, Inc. (NASDAQ:AEMD) closed at $2.36 USD, losing -$0.04 (-1.67%) from the previous close of $2.40. The stock is currently mid-range between its 52-week high and low $1.36 and $35.20. With a market capitalization of about $1.80 million, Aethlon Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.50). Key stats such as the average daily volume over the past year has been around 41.79 thousand shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Aethlon Medical, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO James Frakes, the company employs approximately 14 people and listed since March 04, 1999. Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States.

Aethlon Medical, Inc. has 1.57 million shares outstanding. The public float is 1.24 million shares, elevated short interest at 2.25% of float. This equals 35.09 thousand shares. The short ratio is 1.37 days. Institutional investors hold 4.94% of the float. Insiders own 1.9%. BROENNIMAN EDWARD G holds 282.17 thousand shares, BARRY FRANKLYN S JR has 106.59 thousand shares and Shah Chetan has 16.64 thousand shares.

Aethlon Medical, Inc. generated EPS of -$45.83 over the past year. Five-year average earnings growth is 43.53%. Wall Street analysts project EPS growth of 82.0% annually over the next five years. The latest quarter delivered EPS of -$2.45. The next quarter is forecast at -$2.01. Next year's EPS is expected at -$5.78. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.50 to $1.50. The high target offers -36.44% upside. The low target suggests -36.44% downside. The mean target is $1.50. This offers -36.44% upside. Aethlon Medical, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended February 12, 2026, missed forecasts by 21.89%. The prior quarter beat by 120.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 13, 2024.

Aethlon Medical, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $3.11. This means the shares are trading below this model’s fair value.

Aethlon Medical, Inc. trades at a P/E ratio of -0.17, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.29 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also above market averages.

Our AI price prediction model suggests that Aethlon Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 3.81%, with price expected at $2.45 by May 19, 2026, within a range of $2.30 to $2.62 3-Month Outlook: Projected rise of 493.64%, reaching $14.01 by August 03, 2026, with a range of $12.31 to $15.24. 1-Year Outlook: Projected loss of -97.46%, with price at $0.06 by May 05, 2027, within a range of $0.00 to $0.00.

Aethlon Medical, Inc. (NASDAQ:AEMD) shares are flat -2.53% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Aethlon Medical, Inc. trading at a premium to the broader market with a P/E of -0.17. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $5.43, suggesting 130.08% upside. Our AI forecast model points to short-term strength (3.81% over two weeks), a medium-term rise (493.64% over three months), and a longer-term loss (-97.46% over one year), with expected trading ranges indicating moderate volatility.